Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
CRL Price Action
Last 7 days
17.2%
Last 30 days
-0.1%
Last 90 days
-15.2%
Trailing 12 Months
-39.6%
CRL RSI Chart
CRL Valuation
CRL Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
CRL Fundamentals
CRL Revenue
CRL Earnings
CRL Profitability
CRL Investor Care
CRL Alerts
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 4.0B | 0 | 0 | 0 |
| 2024 | 4.1B | 4.1B | 4.1B | 4.0B |
| 2023 | 4.1B | 4.2B | 4.2B | 4.1B |
| 2022 | 3.6B | 3.7B | 3.8B | 4.0B |
| 2021 | 3.0B | 3.3B | 3.4B | 3.5B |
| 2020 | 2.7B | 2.7B | 2.8B | 2.9B |
| 2019 | 2.4B | 2.4B | 2.5B | 2.6B |
| 2018 | 1.9B | 2.0B | 2.1B | 2.3B |
| 2017 | 1.8B | 1.8B | 1.8B | 1.9B |
| 2016 | 1.4B | 1.5B | 1.6B | 1.7B |
| 2015 | 1.3B | 1.3B | 1.3B | 1.4B |
| 2014 | 1.2B | 1.2B | 1.3B | 1.3B |
| 2013 | 1.1B | 1.1B | 1.2B | 1.2B |
| 2012 | 1.1B | 1.1B | 1.1B | 1.1B |
| 2011 | 1.1B | 1.1B | 1.1B | 1.1B |
| 2010 | 1.2B | 1.1B | 1.1B | 1.1B |
| 2009 | 0 | 1.3B | 1.2B | 1.2B |
| 2008 | 0 | 0 | 0 | 1.3B |
Get all data in R, Python etc through our Historical Stock Data APIs
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| CEO | Mr. James C. Foster J.D. |
|---|---|
| WEBSITE | criver.com |
| SECTOR | Healthcare |
| INDUSTRY | Diagnostics & Research |
| EMPLOYEES | 20000 |
